SCHEMBL4350067

SCHEMBL4350067

CCCCCNC(=S)Nc1cccc(F)c1O

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.70
ALDH1A1 P00352 2/20 0.52
GAA P10253 2/20 0.52
HTT P42858 5/20 0.50
LMNA P02545 5/20 0.50
NPC1 O15118 4/20 0.50
RAB9A P51151 4/20 0.50
RECQL P46063 1/20 0.49
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
KMT2A Q03164 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
ALOX12 P18054 1/20 0.45
HPGD P15428 1/20 0.44
MEN1 O00255 1/20 0.44
EPHX2 P34913 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27782813 0.96 SMN1; SMN2 (0.76) SMN1; SMN2ALDH1A1GAAHTTLMNA
SCHEMBL16320691 0.86 SMN1; SMN2 (0.89) SMN1; SMN2ALDH1A1GAAHTTLMNA
SCHEMBL4355850 0.83 SMN1; SMN2 (0.58) SMN1; SMN2ALDH1A1GAAHTTLMNA
SCHEMBL4349349 0.83 EPHX2 (0.62) SMN1; SMN2ALDH1A1HTTLMNAL3MBTL1
SCHEMBL4356036 0.83 HTT (0.60) SMN1; SMN2ALDH1A1HTTLMNARECQL
SCHEMBL27782800 0.79 POLB (0.61) SMN1; SMN2ALDH1A1HTTLMNARECQL
SCHEMBL27761069 0.79 HTT (0.62) SMN1; SMN2ALDH1A1GAAHTTLMNA
SCHEMBL4349397 0.78 SMN1; SMN2 (0.52) SMN1; SMN2ALDH1A1HTTLMNANPC1
SCHEMBL4355894 0.78 NPC1 (0.79) SMN1; SMN2ALDH1A1GAAHTTLMNA
SCHEMBL4354051 0.75 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1GAAHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 SMN1; SMN2 1791/4885ALDH1A1 2565/4885GAA 4010/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 SMN1; SMN2 3250/4885ALDH1A1 2767/4885GAA 3384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.